GlassScriptPhysician profile
Adam Asch
NPI 1154434405
$857.43
in general payments reported to CMS, 2019-2025
21 companies · $182 in 2025
The $182 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.06 · 2021: $31.96 · 2022: $225 · 2023: $163 · 2024: $225 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $554 · Education: $16.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $553.59 |
| Education | $16.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $187.60 | 2019-2025 | Niktimvo, Jakafi |
| Gilead Sciences, INC. | $144.99 | 2021-2022 | |
| Pfizer INC. | $116.51 | 2022-2024 | |
| Recordati_rare_diseases_inc. | $74.30 | 2023-2024 | Sylvant |
| Daiichi Sankyo INC. | $51.32 | 2023-2024 | Vanflyta |
| Celgene Corporation | $44.14 | 2023 | Reblozyl |
| Janssen Biotech, INC. | $41.86 | 2022 | |
| Astellas Pharma US INC | $40.81 | 2024-2025 | Cresemba, Xospata |
| Genzyme Corporation | $35.47 | 2024 | |
| Beigene USA, INC. | $23.19 | 2023 | Brukinsa |
| Legend Biotech USA INC. | $23.00 | 2025 | Carvykti |
| Sobi, INC | $16.51 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $16.23 | 2024 | Tazverik, Onivyde |
| Genentech, INC. | $14.87 | 2019 | |
| Glaxosmithkline, LLC. | $14.66 | 2024 | Ojjaara |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acrotech Biopharma INC. | $11.97 | 2021 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Asch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.